Symptoms in Pediatric Cancer Do Not Coincide with Proxy Reports
the Cancer Therapy Advisor take:
Symptoms are common among children diagnosed with cancer; however, children’s reports of these symptoms do not coincide with proxy reports, according to an article published online in the journal Cancer.
In this study, 60 pediatric patients with cancer and their family caregivers completed the pediatric Memorial Symptom Assessment Scale (pMSAS), which was translated into Spanish.
The median age of the children was 10 years (range, 7 to 18 years) and 62% were male. Approximately 33% of the patients were Spanish-speaking, but the English- and Spanish-speaking participants yielded similar results.
Results showed nine patients (15%) reported no symptoms, while 38 (63%) had greater than or equal to 2 symptoms. Among the younger patients who reported symptoms, fatigue (12 patients; 40%) and itch (9 patients; 30%) were the most common; whereas, pain (15 patients; 50%) and lack of energy (13 patients; 45%) were the most common symptoms among the older children.
The authors noted 14 oncologists completed 25 patients’ pMSAS.
Furthermore, the range of agreement for individual symptoms between the patient and proxy was from a kappa of -0.30 (95% CI: -0.43, -0.01) to 0.91 (95% CI: 0.75, 1.00).
Out of 51 patients with demonstrated symptoms, 3 (6%) had documented treatment recommendations in their electronic health records.
Symptoms are common among children diagnosed with cancer; however, children’s reports of these symptoms do not match proxy reports.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pesticides and Cancer
- Rare Cancer: An Underserved Area of Oncology
- Ultrasonography May Detect Thyroid Cancer Growth Arrest, Negating Need for Treatment
- Pembrolizumab May Benefit Selected Patients With Incurable Metastatic Breast Cancer
- Does Education Level Predict PSA Screening and Prostate Cancer Survival?
- Adjuvant Gefitinib Improves Disease-free Survival Among Patients With NSCLC
- Phase 1 Study of Binimetinib Plus Pexidartinib for GIST
- Phase 2 Study of Nivolumab vs Nivolumab Plus Ipilimumab for GIST
- Pesticides and Cancer
- Goserelin Mitigates Risk of Ovarian Failure, Improves Breast Cancer Survival Rate